Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Major metabolic pathway for N-methyl-2-pyrrolidone in humans

Åkesson, Bengt LU and Jönsson, Bo A LU (1997) In Drug Metabolism and Disposition 25(2). p.267-269
Abstract
The aim was to study the metabolic pathway for N-methyl-2-pyrrolidone (NMP) in humans. Three healthy male volunteers were administered 100 mg NMP orally. All urine was collected during nine consecutive days. The identification and quantification of the metabolites were performed by gas chromatography/mass spectrometry (GC/MS). NMP, 5-hydroxy-N-methyl-2-pyrrolidone (5-HNMP), N-methylsuccinimide (MSI), and 2-hydroxy-N-methylsuccinimide (2-HMSI) were found in urine. The mean excreted fractions for NMP, 5-HNMP, MSI, and 2-HMSI were 0.8%, 44%, 0.4%, and 20%, respectively. There was no conjugation with glucoronic acid or sulfate or either 5-HNMP or 2-HMSI. One-third of the orally dosed NMP was not recovered in urine as either NMP, 5-HNMP, MSI,... (More)
The aim was to study the metabolic pathway for N-methyl-2-pyrrolidone (NMP) in humans. Three healthy male volunteers were administered 100 mg NMP orally. All urine was collected during nine consecutive days. The identification and quantification of the metabolites were performed by gas chromatography/mass spectrometry (GC/MS). NMP, 5-hydroxy-N-methyl-2-pyrrolidone (5-HNMP), N-methylsuccinimide (MSI), and 2-hydroxy-N-methylsuccinimide (2-HMSI) were found in urine. The mean excreted fractions for NMP, 5-HNMP, MSI, and 2-HMSI were 0.8%, 44%, 0.4%, and 20%, respectively. There was no conjugation with glucoronic acid or sulfate or either 5-HNMP or 2-HMSI. One-third of the orally dosed NMP was not recovered in urine as either NMP, 5-HNMP, MSI, or 2-HMSI. The half-lives for 5-HNMP, MSI, and 2-HMSI in urine were approximately 4, 8, and 17 hr, respectively. (Less)
Please use this url to cite or link to this publication:
author
and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Drug Metabolism and Disposition
volume
25
issue
2
pages
267 - 269
publisher
American Society for Pharmacology and Experimental Therapeutics
external identifiers
  • pmid:9029058
  • scopus:0342275194
ISSN
1521-009X
language
English
LU publication?
yes
id
7c5cc1b4-953f-4d4d-9b0c-8318e943f362 (old id 1111499)
alternative location
http://dmd.aspetjournals.org/cgi/content/full/25/2/267
date added to LUP
2016-04-01 12:10:57
date last changed
2022-03-28 21:23:57
@article{7c5cc1b4-953f-4d4d-9b0c-8318e943f362,
  abstract     = {{The aim was to study the metabolic pathway for N-methyl-2-pyrrolidone (NMP) in humans. Three healthy male volunteers were administered 100 mg NMP orally. All urine was collected during nine consecutive days. The identification and quantification of the metabolites were performed by gas chromatography/mass spectrometry (GC/MS). NMP, 5-hydroxy-N-methyl-2-pyrrolidone (5-HNMP), N-methylsuccinimide (MSI), and 2-hydroxy-N-methylsuccinimide (2-HMSI) were found in urine. The mean excreted fractions for NMP, 5-HNMP, MSI, and 2-HMSI were 0.8%, 44%, 0.4%, and 20%, respectively. There was no conjugation with glucoronic acid or sulfate or either 5-HNMP or 2-HMSI. One-third of the orally dosed NMP was not recovered in urine as either NMP, 5-HNMP, MSI, or 2-HMSI. The half-lives for 5-HNMP, MSI, and 2-HMSI in urine were approximately 4, 8, and 17 hr, respectively.}},
  author       = {{Åkesson, Bengt and Jönsson, Bo A}},
  issn         = {{1521-009X}},
  language     = {{eng}},
  number       = {{2}},
  pages        = {{267--269}},
  publisher    = {{American Society for Pharmacology and Experimental Therapeutics}},
  series       = {{Drug Metabolism and Disposition}},
  title        = {{Major metabolic pathway for N-methyl-2-pyrrolidone in humans}},
  url          = {{http://dmd.aspetjournals.org/cgi/content/full/25/2/267}},
  volume       = {{25}},
  year         = {{1997}},
}